HomeCompareCSCI vs ABBV

CSCI vs ABBV: Dividend Comparison 2026

CSCI yields 73.53% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSCI wins by $1.14M in total portfolio value
10 years
CSCI
CSCI
● Live price
73.53%
Share price
$2.72
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.24M
Annual income
$336,833.40
Full CSCI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CSCI vs ABBV

📍 CSCI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSCIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSCI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSCI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSCI
Annual income on $10K today (after 15% tax)
$6,250.00/yr
After 10yr DRIP, annual income (after tax)
$286,308.39/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CSCI beats the other by $265,252.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSCI + ABBV for your $10,000?

CSCI: 50%ABBV: 50%
100% ABBV50/50100% CSCI
Portfolio after 10yr
$670.2K
Annual income
$180,802.58/yr
Blended yield
26.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CSCI
No analyst data
Altman Z
-1.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSCI buys
0
ABBV buys
0
No recent congressional trades found for CSCI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSCIABBV
Forward yield73.53%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1.24M$102.3K
Annual income after 10y$336,833.40$24,771.77
Total dividends collected$1.06M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSCI vs ABBV ($10,000, DRIP)

YearCSCI PortfolioCSCI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$18,053$7,352.94$11,550$430.00+$6.5KCSCI
2$31,722$12,405.81$13,472$627.96+$18.3KCSCI
3$54,316$20,373.25$15,906$926.08+$38.4KCSCI
4$90,720$32,601.67$19,071$1,382.55+$71.6KCSCI
5$147,960$50,889.65$23,302$2,095.81+$124.7KCSCI
6$235,886$77,568.79$29,150$3,237.93+$206.7KCSCI
7$367,972$115,574.20$37,536$5,121.41+$330.4KCSCI
8$562,227$168,496.11$50,079$8,338.38+$512.1KCSCI
9$842,186$240,603.66$69,753$14,065.80+$772.4KCSCI
10$1,237,972$336,833.40$102,337$24,771.77+$1.14MCSCI

CSCI vs ABBV: Complete Analysis 2026

CSCIStock

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Full CSCI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CSCI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSCI vs SCHDCSCI vs JEPICSCI vs OCSCI vs KOCSCI vs MAINCSCI vs JNJCSCI vs MRKCSCI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.